In February 2020, Trulicity was approved by the US FDA for new indications for use in adult patients with type 2 diabetes who have cardiovascular (CV) diseases or multiple cardiovascular risk factors to reduce the risk of major adverse cardiovascular events (MACE)
Some patients do well at lower doses and experience excellent results without needing to escalate to the maximum
Now we have the first steps to be able to diagnose it, and also theres hope for treatment, because by using chemistry, we can counter the toxicity of these drugs and actually make them safe for general application.
It is essential to remember that these treatments are medications, with precise indications, dose progression, and medical follow-up
Possible preventative/rehabilitative role of gliflozins in OSA and T2DM
Good questions to ask: Are my results normal